Pfizer reaffirms FY26 adjusted EPS range $2.80 to $3
Pfizer has reaffirmed its FY26 financial guidance, maintaining an adjusted EPS range of $2.80 to $3.00 and a revenue forecast of $59.5B to $62.5B. The announcement was made via a regulatory filing with the SEC.
*this image is generated using AI for illustrative purposes only.
Pfizer has reaffirmed its financial guidance for FY26, maintaining its adjusted earnings per share (EPS) outlook and revenue projections. The company expects adjusted EPS to land between $2.80 and $3.00, while revenue is anticipated to range from $59.5B to $62.5B.
The guidance was provided in a regulatory filing submitted to the Securities and Exchange Commission (SEC). The document confirms the company's previous outlook without revision, signaling stability in its operational expectations for the year.
Financial Outlook
The following table outlines the key financial metrics reaffirmed by Pfizer for FY26:
| Metric | Range |
|---|---|
| Adjusted EPS | $2.80 - $3.00 |
| Revenue | $59.5B - $62.5B |
The reaffirmation comes as Pfizer continues to navigate market conditions. The company's decision to hold steady on its guidance suggests confidence in its ability to meet the projected targets despite potential market volatility.
Historical Stock Returns for Pfizer
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.12% | -0.86% | -6.70% | -11.12% | -21.73% | -16.09% |
What specific product launches or pipeline advancements are expected to drive revenue within the projected range?
How might potential changes in healthcare policy or patent cliffs impact Pfizer's ability to maintain its FY26 guidance?
What strategies is Pfizer employing to mitigate market volatility and ensure stability in its adjusted EPS?
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
